本文選題：左旋多巴　切入點：恩他卡朋　出處：《中國臨床藥理學雜志》2016年14期

【摘要】：目的觀察左旋多巴聯合恩他卡朋治療帕金森病的臨床療效及安全性。方法將54例原發(fā)性帕金森病患者隨機分為對照組27例和試驗組27例。對照組予以口服左旋多巴0.25 g,tid;試驗組在對照組的基礎上,予以口服恩他卡朋0.2 g,tid。2組患者均治療16周。比較2組患者的臨床療效、血清白細胞介素(IL)-1β、IL-6、丙二醛、超氧化物歧化酶(SOD)和谷胱甘肽過氧化物酶(GSH-Px)水平、統(tǒng)一帕金森病評分量表(UPDRS)評分以及不良反應發(fā)生率。結果治療后,試驗組的總有效率為92.59%(25/27例)顯著高于對照組的70.37%(19/27例,P0.05)。治療后,試驗組與對照組的血清IL-1β分別為(32.32±0.32),(45.35±6.01)pg·L-1;IL-6分別為(4.03±0.54),(6.78±0.82)pg·L~(-1);丙二醛水平分別為(14.72±2.21),(19.37±2.44)mmol·mg~(-1);UPDRS-Ⅱ評分分別為(3.98±1.56),(11.74±1.25)分;UPDRS-Ⅲ評分分別為(26.43±3.28),(31.54±4.17)分,且試驗組治療后的上述指標均顯著低于對照組(P0.05)。治療后,試驗組與對照組的血清SOD分別為(135.55±17.84),(120.93±18.38)U·μg~(-1)、GSH-Px分別為(99.74±12.43),(90.73±10.84)U·μg~(-1),且試驗組治療后的上述指標均顯著高于對照組(P0.05)。試驗組和對照組的不良反應以神經系統(tǒng)、消化系統(tǒng)和皮膚系統(tǒng)的癥狀為主,其不良反應發(fā)生率分別為11.11%和14.81%,差異無統(tǒng)計學意義(P0.05)。結論左旋多巴聯合恩他卡朋治療帕金森病的臨床療效確切,且不增加不良反應發(fā)生率。
[Abstract]:Objective to observe the clinical efficacy and safety of Levodopa combined with Entakaben in the treatment of Parkinson's disease. Methods 54 patients with primary Parkinson's disease were randomly divided into control group (n = 27) and trial group (n = 27). The experimental group was based on the control group. The clinical efficacy, serum levels of IL-6, malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) were compared between the two groups. Results after treatment, the total effective rate of the trial group was 92.5925 / 27 cases, which was significantly higher than that of the control group (70.37% / 27 cases, P 0.05). The serum IL-1 尾 of test group and control group were 32.32 鹵0.32 鹵0.32 鹵0.32 鹵0.32 鹵0.32 鹵0.32 鹵0.32 鹵0.32 鹵0.32 鹵0.32 鹵0.32 鹵6.01)pg L ~ (-1) and 6.78 鹵6.78 鹵0.82)pg 路L ~ (-1) of IL-6, respectively, and the level of malondialdehyde (MDA) were 14.72 鹵2.21 鹵1.37 鹵1.37 鹵1.56 Mg-1 / 1 respectively. The scores of UPDRS- 鈪，

本文編號：1666837